Nystagmus oxcarbazepine

Neurosensory side effects (e.g., diplopia, blurred vision, nystagmus, ataxia, dizziness, and headache) are the most common, occurring in 35% to 50% of patients initially. It may induce hyponatremia, and the incidence may increase with age. Hyponatremia occurs less frequently than with oxcarbazepine. 

Patients with hypersensitivity reactions to carbamazepine can be expected to show cross-sensitivity (e.g., rash) or related problems to oxcarbazepine. The improved toxicity profile for oxcarbazepine when compared to CBZ may result from absence of the epoxide or CBZ-iminoquinone metabolites (47). The most common side effects are headache, dizziness, nystagmus, blurred vision, somnolence, nausea, ataxia, and fatigue. The Incidence of adverse effects has been related to elevated serum MHD concentrations (52). Adverse effects on cognitive status, hyponatremia, and serious dermatological reactions have been reported, as has hyponatremia (53). 

A 10-year-old boy with refractory epilepsy developed symptoms and signs of oxcarbazepine toxicity (vomiting, drowsiness, hyperkinesia, ataxia, and nystagmus) after two doses of clarithromycin 250 mg. The symptoms resolved on withdrawal of the clarithromycin. 

Drug dosage regimens The efficacy and tolerability of an oral oxcarbazepine loading dose of 30 mg/kg was assessed in 40 adolescent and adult patients. The most common adverse effect was dizziness, followed by nausea/ vomiting, nystagmus, ataxia, and diplopia. Most of these adverse effects occurred shortly after administration, and did not correlate with plasma levels of the medication [113 ]. 

---